- Home
- SNCR vs CNTX Comparison
SNCR vs CNTX Comparison
Compare SNCR & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNCR
- CNTX
- Stock Information
- Founded
- SNCR 2000
- CNTX 2015
- Country
- SNCR United States
- CNTX United States
- Employees
- SNCR N/A
- CNTX N/A
- Industry
- SNCR EDP Services
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- SNCR Technology
- CNTX Health Care
- Exchange
- SNCR Nasdaq
- CNTX Nasdaq
- Market Cap
- SNCR 70.9M
- CNTX 75.6M
- IPO Year
- SNCR 2006
- CNTX 2021
- Fundamental
- Price
- SNCR $6.23
- CNTX $0.92
- Analyst Decision
- SNCR Strong Buy
- CNTX Strong Buy
- Analyst Count
- SNCR 1
- CNTX 5
- Target Price
- SNCR $13.00
- CNTX $5.25
- AVG Volume (30 Days)
- SNCR 62.9K
- CNTX 86.7K
- Earning Date
- SNCR 11-11-2025
- CNTX 11-05-2025
- Dividend Yield
- SNCR N/A
- CNTX N/A
- EPS Growth
- SNCR N/A
- CNTX N/A
- EPS
- SNCR N/A
- CNTX N/A
- Revenue
- SNCR $171,870,000.00
- CNTX N/A
- Revenue This Year
- SNCR $1.51
- CNTX N/A
- Revenue Next Year
- SNCR $5.43
- CNTX N/A
- P/E Ratio
- SNCR N/A
- CNTX N/A
- Revenue Growth
- SNCR 2.54
- CNTX N/A
- 52 Week Low
- SNCR $5.25
- CNTX $0.49
- 52 Week High
- SNCR $15.46
- CNTX $2.59
- Technical
- Relative Strength Index (RSI)
- SNCR 51.19
- CNTX 67.83
- Support Level
- SNCR $5.41
- CNTX $0.81
- Resistance Level
- SNCR $6.27
- CNTX $0.87
- Average True Range (ATR)
- SNCR 0.32
- CNTX 0.05
- MACD
- SNCR 0.11
- CNTX 0.00
- Stochastic Oscillator
- SNCR 86.73
- CNTX 100.00
About SNCR Synchronoss Technologies Inc.
Synchronoss Technologies Inc is a provider of white-label cloud, messaging, digital and network management solutions that enable its customers to keep subscribers, systems, networks and content in sync. The Synchronoss Personal CloudTM solution is designed to create an engaging and trusted customer experience through ongoing content management and engagement. The Synchronoss Personal CloudTM platform is a secure and scalable, white-label platform that allows its customers' subscribers to backup and protect, engage with, and manage their personal content. The company derives revenue from subscriptions and transaction-based fees. A majority of the firm's revenue is generated in the United States, and the rest is from countries across the world.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.